Prosecution Insights
Last updated: October 02, 2026

The United Bio-Technology (Hengqin) Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

The United Bio-Technology (Hengqin) Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific action is assigned to REYNOLDS, FRED H, who is identified as the busiest examiner for the portfolio. The concentration of the entire pending workload under a single individual suggests a focused prosecution effort at this stage of the company's patent strategy.

The portfolio's activity is limited to 1 distinct examiner and a distinct art unit. This indicates that the company's current legal challenges are confined to a specific regulatory niche within the broader biotechnology field. Practitioners should note that the busiest examiner pending count matches the total pending office actions for the entire portfolio, meaning there is no diversification of examiner perspectives. This focus requires a precise response strategy tailored to the specific preferences of the assigned official. Having only a distinct examiner involved means that the company's immediate patent outcomes depend on the review of REYNOLDS, FRED H. The presence of a distinct art unit further suggests a narrow technical scope for the company's current intellectual property efforts.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
REYNOLDS, FRED H 1 33.0% +39.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18563552 Multi-Agonist and Use Thereof REYNOLDS, FRED H —

Top Art Units

Art UnitApps
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18563552 Multi-Agonist and Use Thereof REYNOLDS, FRED H 1658 DP Final Rejection — Pending Nov 22, 2023

Managing The United Bio-Technology (Hengqin) Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month